SoHi Partners

We team with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity, and operations. Anzu manages approximately $1 billion in strategic assets across three venture funds, a mezzanine revenue-based investing fund (“RBI”), and a special purpose acquisition company (“SPAC”). The venture capital funds focus on investments in early-stage companies, ranging from pre-revenue to post-commercialization, where we have deep knowledge and relationships to drive value for investors. RBI provides capital through a non-dilutive preferred share vehicle to post-revenue companies, offering an alternative to traditional venture and debt financing. Anzu Special Acquisition Corp I seeks to identify high-quality businesses with transformative technologies for industrial applications. Anzu primarily invests in companies across North America, Europe, and Asia Pacific. Founded in 2014, Anzu Partners operates a robust investment platform for industrial and life science technology companies. Anzu’s current portfolio consist of 25+ portfolio companies, and the firm has 12+ investment professionals, 260+ fund investors, and 40+ portfolio support staff. We have had several meaningful exits and manage an active pipeline of new opportunities in diligence, tracked through firm-wide pipeline reviews that cover 400-500 industrial and life science technology companies per year across the globe.

We back promising teams by providing both financial and business support to build the next generation of game-changing technologies companies in the field of Life Sciences. We invest in ambitious early stage start-ups and SMEs with innovative products globally, mainly across Europe and Israel. We bring strong entrepreneurial and financial expertise to portfolio companies well beyond just capital, relying on a wide network of clinicians and industry experts. We have established relationships with selected industrial partners to assist our founders in accelerating their development. We invest in people, believing that a strong and dedicated team is one of the most important factors in the success of our investments. We aim to work together with entrepreneurs to develop successful businesses as an active and well-connected investor. We invest for people, supporting the growth of companies and people that will reshape the medical world, answering real medical needs, saving lives and providing a better quality of life for patients and care-givers. An overall positive impact that will produce intrinsic value for both investors and society.

Biospring Partners was founded in 2020 to invest in companies with the potential to fundamentally shift how technology is utilized across the life sciences sector. Michelle Dipp and Jennifer Lum came together to combine their experience in healthcare, technology, investing and operations to offer a differentiated approach to growth equity. Expanding the potential of life sciences technology We focus on identifying long-term themes within life sciences technology. We build trusted partnerships with management teams to support the growth of their businesses. Sectors we invest in Biospring invests in growth-stage B2B companies that are driving innovation across the life sciences industry and beyond. Our Approach We are a trusted partner that thrives in building long term strategic partnerships. We work closely alongside our companies to broaden their ambition and strengthen their path to growth. Our Investment Criteria$10M+ in annual revenue 30%+ revenue growth Diverse customer base

Asabys is an investment firm based in Barcelona, investing in healthcare and life-sciences innovation. Impact: We want to push the boundaries of science and medicine improving patient’s life Disruptive: We look for highly innovative and transformative technologies Hands-on: We consider ourselves partners and collaborators to our portfolio companies

We’re not just an investor. We’re all about being an active stakeholder. Identify: We are renown for identifying early stage technologies and start-ups. Our established network and expertise enable us to do so. Incubate: We run an incubation center for our early stage start-ups that need support in early growth stage. Accelerate: We act as business development managers for our portfolio companies. We help companies collaborate in the bio-ecosystem. Funding to IPO: We back our portfolio companies in the long run. We accompany them from the very start to their success. We take entrepreneurial ideas into reality. We have been investing in the past, present and into the future. Korea to Global: Using our global pharmaceutical network we source licensing & research collaboration deals for our portfolios. Korea to China: Through collaboration with our network in China we help value up our portfolio companies. Each year we host ‘China Korea Bio Business Networking Day’ to connect Korean biotechs with Chinese pharmaceuticals and buy-side investors. Korea to Vietnam: We invest in local Vietnam start-ups and build up platforms, formulate ecosystems to accommodate the growth of future industries. And beyond… We are creators and path makers We create synergy, matrix and we take the first step for others to follow.

We are an investment firm with more than 25 years of experience backing transformational healthcare and biotech companies. We see the world through an entrepreneur’s eyes. We thrive on collaborating with groundbreaking innovators and repeat entrepreneurs. Our roots are deep in healthcare and science. We have built and nurtured our network over more than two decades – including some of the world’s most prestigious companies, syndicate partners, universities and research institutions. We have built and nurtured our network over more than two decades – including some of the world’s most prestigious companies, syndicate partners, universities and research institutions. Groundbreaking expertiseHealthcare: Our healthcare portfolio companies target innovative care delivery models, such as digital health, consumer-centric businesses, patient and provider solutions, and data science and analytics. Life sciences and biotechnology: Our life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics and genomics.